2009-11-09 14:55:05 -

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, reports that On Monday and Tuesday of this week, the 7th Annual Vaccines: All Things Considered Conference is taking place in Washington, DC. Investors should keep an eye on this event, which serves as a one-stop destination

for valuable updates and exposure on all aspects of vaccine research, development, regulations, and policy via key, intimate presentations by innovative biotech companies and government regulators.

Organizers aim to provide exposure to all avenues of vaccine research, development, regulations and policy and updates on the flu pandemic, bio-defense policy. The National Vaccine Plan will also be addressed and discussed.

Several government officials, including representatives from the United States Department of Health and Human Services, National Research Council of Canada, National Institutes of Health, National Institute of Allergy and Infectious Disease, and the Food and Drug Administration, come together at this conference with representatives from several key biotech and pharmaceutical companies.

"The research and discovery of vaccines to fight globally prevalent diseases has been a major focus of the pharmaceutical industry’s biggest players for decades," say members of the conference's organizing committee. "The pharmaceutical world has recently been rocked by the pending expiration of patents on several major block-buster drugs. How does this affect funding for vaccine research and development? What will be the path forward? How will the generic drug industry affect the vaccines market? These are just a few of the questions the Vaccines conference will address and answer."

Scheduled to present the event's opening remarks and to moderate several of the key presentation sessions is Dr.Daniel Zimmerman, Ph.D., Senior Vice President Research and Development, Cellular Immunology for CEL-SCI Corporation (AMEX:CVM). Zimmerman's work at the company in partnership with several research university partners has been attracting a great deal of attention in both the H1N1 influenza and inflammatory disease space lately.

Companies who will share the spotlight in front of some of the key officials from the government agencies include.

Ibis Biosciences, Inc., Immunovaccine, Inc.(CVE:IMV), Advaxis, Inc.(OTC:ADXS) , EpiVax, VaxArt, VaxDesign, and at least three big pharmaceutical companies including Novartis (NYSE:NVS), Sanofi Pasteur, and Merck (NYSE:MRK).

Representatives from the academic research field will include.

Dr. Kenneth S. Rosenthal, Ph.D., ProfessorMicrobiology/Immunology, Northeastern Ohio Universities Colleges of Medicine and Pharmacy


Pirouz DaftarianHead, Biological Modifiers Laboratory, University of Miami


The complete report is available now at BioMedReports.Com.

biomedreports.com/articles/most-popular/17010-dc-vaccine-confere .. :

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here.

biomedreports.com/fda-calendar/fda-calendar.html :

About BioMedReports.Com


BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to BioMedReports.com :

BioMedReports.ComM. Davila, +1 323-472-4480Fax: +1
888-210-3556Assistant Editor info@biomedreports.com : mailto:info@biomedreports.com